TY - JOUR
T1 - Effect of propranolol versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients ≥62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction ≥40%
AU - Aronow, Wilbert S.
AU - Ahn, Chul
AU - Mercando, Anthony D.
AU - Epstein, Stanley
AU - Kronzon, Itzhak
PY - 1994/8/1
Y1 - 1994/8/1
N2 - Patients with complex ventricular arrhythmias associated with heart disease are at increased risk for new cardiac events.1-5 However, there are no hard data from prospective, randomized, double-blind clinical trials documenting that abolition or reduction of ventricular tachycardia (VT) or complex ventricular arrhythmias by antiarrhythmic drugs will decrease cardiac events or mortality.6 Beta blockers reduce ventricular arrhythmias in postinfarction patients.7 In the Beta-Blocker Heart Attack Trial, propranolol reduced sudden death by 28% in the subgroup of patients with complex ventricular arrhythmias and 16% in the subgroup of patients without ventricular arrhythmias.8 In the present report, we present the results from a prospective, randomized study correlating the effect of propranolol versus no antiarrhythmic drug on the incidences of sudden cardiac death, total cardiac death, and total death in 245 patients aged ≥62 years with heart disease, complex ventricular arrhythmias and no sustained VT detected by 24-hour ambulatory electrocardiography, and a left ventricular (LV) ejection fraction ≥40.
AB - Patients with complex ventricular arrhythmias associated with heart disease are at increased risk for new cardiac events.1-5 However, there are no hard data from prospective, randomized, double-blind clinical trials documenting that abolition or reduction of ventricular tachycardia (VT) or complex ventricular arrhythmias by antiarrhythmic drugs will decrease cardiac events or mortality.6 Beta blockers reduce ventricular arrhythmias in postinfarction patients.7 In the Beta-Blocker Heart Attack Trial, propranolol reduced sudden death by 28% in the subgroup of patients with complex ventricular arrhythmias and 16% in the subgroup of patients without ventricular arrhythmias.8 In the present report, we present the results from a prospective, randomized study correlating the effect of propranolol versus no antiarrhythmic drug on the incidences of sudden cardiac death, total cardiac death, and total death in 245 patients aged ≥62 years with heart disease, complex ventricular arrhythmias and no sustained VT detected by 24-hour ambulatory electrocardiography, and a left ventricular (LV) ejection fraction ≥40.
UR - http://www.scopus.com/inward/record.url?scp=0028031501&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028031501&partnerID=8YFLogxK
U2 - 10.1016/0002-9149(94)90369-7
DO - 10.1016/0002-9149(94)90369-7
M3 - Article
C2 - 7518646
AN - SCOPUS:0028031501
SN - 0002-9149
VL - 74
SP - 267
EP - 270
JO - The American journal of cardiology
JF - The American journal of cardiology
IS - 3
ER -